Assenagon Asset Management
RARX

Assenagon Asset Management’s Ra Pharmaceuticals, Inc. Common Stock RARX Stock Holding History

Assenagon Asset Management’s Portfolio RARX Stock Details RARX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-61,897
Closed -$1.13M – 1195
2018
Q4 		$1.13M Buy
+61,897
New +$972K 0.01% 616

Other funds holding RARX

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MMPI
Morgenthaler Management Partners IX Portola Valley, California $22.6M AUM
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Assenagon Asset Management's RARX Position: Q1 2019 in Review

Assenagon Asset Management sold out of Ra Pharmaceuticals, Inc. Common Stock (RARX) in Q1 2019, closing a stake of 61,897 shares — an estimated $1.13M sold.

Assenagon Asset Management first reported a position in RARX in Q4 2018 and held it in 1 quarter. The position peaked at $1.13M in Q4 2018. 124 funds tracked by Wall St. Rank hold RARX as of Q1 2019.

  • Assenagon Asset Management reported no remaining Ra Pharmaceuticals, Inc. Common Stock position as of Q1 2019 after selling out during the quarter.
  • Assenagon Asset Management sold 61,897 Ra Pharmaceuticals, Inc. Common Stock shares in Q1 2019, an estimated $1.13M.
  • Assenagon Asset Management first reported a position in Ra Pharmaceuticals, Inc. Common Stock in Q4 2018 and held it in 1 quarter.
  • Assenagon Asset Management's Ra Pharmaceuticals, Inc. Common Stock position peaked at $1.13M in Q4 2018.
  • 124 funds tracked by Wall St. Rank held Ra Pharmaceuticals, Inc. Common Stock as of Q1 2019.

Based on Assenagon Asset Management's 13F filing for Q1 2019, filed 26 Apr 2019.